EYA1 Polyclonal Antibody

$Lane 1: Human HepG2 cell lysates; Lane 2: Human HeLa cell lysates; Lane 3: Human SH-SY5Y cell lysates probed with EYA1 Polyclonal Antibody, Unconjugated (bs-13124R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Human HepG2 cell lysates; Lane 2: Human HeLa cell lysates; Lane 3: Human SH-SY5Y cell lysates probed with EYA1 Polyclonal Antibody, Unconjugated (bs-13124R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

Reactivity

Human

Overview
Catalog #	bs-13124R
Product Name	EYA1 Polyclonal Antibody
Applications	WB
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human EYA1
Clonality	Polyclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20C for 12 months.
Target
Gene ID	2138
Synonyms	BOP; BOR; Eya1; EYA1_HUMAN; eyes absent 1; eyes absent 1 homolog; eyes absent homolog 1 Drosophila; Eyes absent homolog 1; eyes absent homolog1; MGC141875.
Background	A gene on chromosome 8q13.3 encodes EYA1 (eyes absent), a protein with 16 exons. EYA1 is one of four members of the eyes absent family. A 271 amino acid domain at the carboxyl terminal is highly conserved amongst the members of the eyes absent family, while the PST (proline-serine-threonin)-rich amino terminal is highly divergent. EYA is expressed in flexor tendons and the developing central nervous system, kidney, eye and ear. EYA1 acts a transcriptional activator in connective tissue patterning through its PST domain, which functions as a transactivation domain. EYA1 plays a critical role in the development of the inner ear and kidney. EYA is involved in early inductive signaling, acting upstream of GDNF. EYA1 has been implicated in the autosomal dominant disorders branchio-oto-renal (BOR) syndrome and branhio-oto (BO) syndrome.
Application Dilution
WB	1:500-2000